Trial · NCT01813539
A Study of ARGX-110 in Participants With Advanced Malignancies
NCT01813539, Phase 1, Phase 2, Completed, OncoVerity, Inc.
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. A Study of ARGX-110 in Participants With Advanced Malignancies. Trials, record NCT01813539. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01813539
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study of ARGX-110 in Participants With Advanced Malignancies
- NCT number
- NCT01813539
- Status
- Completed
- Phases
- Phase 1, Phase 2
- Enrollment
- 99 participants, actual
- Lead sponsor
- OncoVerity, Inc.
- Conditions
- Neoplasms
- Interventions
- ARGX-110
- First posted
- 2013-03-19
- Last updated
- 2023-08-09
- Other registries' IDs
- eudract:2012-005046-38
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants with Dose Limiting Toxicity (DLT) | 21 days | DLT is defined as drug-related grade 3 or 4 clinical adverse event (AE) occurring during the 21 days (3 weeks) following the first dose of ARGX-110. |
| Secondary | Plasma Concentrations of ARGX-110 | Up to 2 years | Plasma concentration of ARGX-110 will be assessed. |
| Secondary | Biomarkers (CD70 qPCR and sCD27) of ARGX-110 biological activity | Up to 2 years | Biomarkers (CD70 quantitative polymerase chain reaction \[CD70 qPCR\] and soluble CD27 \[sCD27\]) will be measured in serum and on tumor samples to correlate systemic drug effects with AE and Tumor response. |
| Secondary | Number of Participants who Achieve a Tumor Response | Up to 2 years | Tumor response will be assessed according to RECIST. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 24492296 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01813539
GET https://conductscience.org/api/trials/v1/NCT01813539/registered